135 related articles for article (PubMed ID: 37670619)
1. [Efficacy of neoadjuvant therapy on HER2-positive breast cancer: a clinicopathological analysis].
Zhu P; Lyu H; Bai QM; Shui RH; Xu XL; Yang WT
Zhonghua Bing Li Xue Za Zhi; 2023 Sep; 52(9):907-911. PubMed ID: 37670619
[No Abstract] [Full Text] [Related]
2. Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer.
Choi JH; Jeon CW; Kim YO; Jung S
Medicine (Baltimore); 2020 Nov; 99(46):e23053. PubMed ID: 33181670
[TBL] [Abstract][Full Text] [Related]
3. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry.
Niikura N; Tomotaki A; Miyata H; Iwamoto T; Kawai M; Anan K; Hayashi N; Aogi K; Ishida T; Masuoka H; Iijima K; Masuda S; Tsugawa K; Kinoshita T; Nakamura S; Tokuda Y
Ann Oncol; 2016 Mar; 27(3):480-7. PubMed ID: 26704052
[TBL] [Abstract][Full Text] [Related]
4. Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer.
Chen HL; Chen Q; Deng YC
Medicine (Baltimore); 2021 Nov; 100(44):e27632. PubMed ID: 34871229
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study.
Zhou M; Wang S; Wan N; Yuan S; Hu X; Zhou W; Qing B; Liu M; Sun W; Fan P; Wang J; Cao H; Xu H; Dai B; Tang P; Qian L; Zhao X; Xiao J; Zhou H; Hu J; Ding L; Tripodi D; Zdenkowski N; O'Keefe TJ; Sanchez AM; Chen L; Zhang P; Xu F
Ann Transl Med; 2022 Dec; 10(24):1387. PubMed ID: 36660637
[TBL] [Abstract][Full Text] [Related]
6. PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China.
Liu X; Liu Z; Li C; Song X; Wang X; Li S; Yu Z
World J Surg Oncol; 2023 Sep; 21(1):296. PubMed ID: 37723497
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
8. [Role of clustered HER2/neu amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II-III breast cancer].
Kolyadina IV; Zavalishina LE; Ganshina IP; Andreeva YY; Frank GA; Gordeeva OO; Zhukova LG; Meshcheryakov AA; Savelov NA; Tuzova EA; Morozov DA; Poddubnaya IV
Arkh Patol; 2019; 81(6):56-62. PubMed ID: 31851193
[TBL] [Abstract][Full Text] [Related]
9. The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
Sánchez-Muñoz A; Plata-Fernández YM; Fernández M; Jaén-Morago A; Fernández-Navarro M; de la Torre-Cabrera C; Ramirez-Tortosa C; Lomas-Garrido M; Llácer C; Navarro-Perez V; Alba-Conejo E; Sánchez-Rovira P
Clin Breast Cancer; 2013 Apr; 13(2):146-52. PubMed ID: 23318089
[TBL] [Abstract][Full Text] [Related]
10. HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial.
Guarneri V; Bras-Maristany F; Dieci MV; Griguolo G; Par L; Mar Ín-Aguilera M; Miglietta F; Bottosso M; Giorgi CA; Blasco P; Castillo O; Galv N P; Vivancos A; Villagrasa P; Parker JS; Perou CM; Conte P; Prat A
EBioMedicine; 2022 Nov; 85():104320. PubMed ID: 36374768
[TBL] [Abstract][Full Text] [Related]
11. Somatic mutations in a multigene panel and impact on prognosis based on TP53 status in Chinese HER2-positive patients undergoing neoadjuvant therapy: A single-institution retrospective cohort.
Xiong M; Wang X; Liu D; Xiu B; Zhang Q; Chi W; Goh CW; Zhang L; Chen M; Ren H; Shao ZM; Yang B; Wu J
Cancer Med; 2024 Jan; 13(2):e6955. PubMed ID: 38379328
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.
Kogawa T; Fujii T; Wu J; Harano K; Fouad TM; Liu DD; Shen Y; Masuda H; Krishnamurthy S; Chavez-MacGregor M; Lim B; Murthy RK; Valero V; Tripathy D; Ueno NT
Oncologist; 2020 Jun; 25(6):e909-e919. PubMed ID: 32003919
[TBL] [Abstract][Full Text] [Related]
13. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
Guarneri V; Dieci MV; Bisagni G; Frassoldati A; Bianchi GV; De Salvo GL; Orvieto E; Urso L; Pascual T; Paré L; Galván P; Ambroggi M; Giorgi CA; Moretti G; Griguolo G; Vicini R; Prat A; Conte PF
Ann Oncol; 2019 Jun; 30(6):921-926. PubMed ID: 30778520
[TBL] [Abstract][Full Text] [Related]
14. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
Bianchini G; Kiermaier A; Bianchi GV; Im YH; Pienkowski T; Liu MC; Tseng LM; Dowsett M; Zabaglo L; Kirk S; Szado T; Eng-Wong J; Amler LC; Valagussa P; Gianni L
Breast Cancer Res; 2017 Feb; 19(1):16. PubMed ID: 28183321
[TBL] [Abstract][Full Text] [Related]
15. HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer.
Zhao J; Krishnamurti U; Zhang C; Meisel J; Wei Z; Suo A; Aneja R; Li Z; Li X
Pathol Res Pract; 2020 Nov; 216(11):153155. PubMed ID: 32871536
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant therapy for early human epidermal growth factor receptor 2 positive breast cancer in China: A multicenter real-world study (CSBrS-015).
Cheng Y; Xiang H; Xin L; Duan X; Liu Y;
Chin Med J (Engl); 2022 Oct; 135(19):2311-2318. PubMed ID: 36535009
[TBL] [Abstract][Full Text] [Related]
17. Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.
Singer CF; Tan YY; Fitzal F; Steger GG; Egle D; Reiner A; Rudas M; Moinfar F; Gruber C; Petru E; Bartsch R; Tendl KA; Fuchs D; Seifert M; Exner R; Balic M; Bago-Horvath Z; Filipits M; Gnant M;
Clin Cancer Res; 2017 Jul; 23(14):3676-3683. PubMed ID: 28143867
[No Abstract] [Full Text] [Related]
18. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
Masuda N; Ohtani S; Takano T; Inoue K; Suzuki E; Nakamura R; Bando H; Ito Y; Ishida K; Yamanaka T; Kuroi K; Yasojima H; Kasai H; Takasuka T; Sakurai T; Kataoka TR; Morita S; Ohno S; Toi M
Breast Cancer Res Treat; 2020 Feb; 180(1):135-146. PubMed ID: 31953696
[TBL] [Abstract][Full Text] [Related]
19. HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.
Stocker A; Hilbers ML; Gauthier C; Grogg J; Kullak-Ublick GA; Seifert B; Varga Z; Trojan A
PLoS One; 2016; 11(7):e0159176. PubMed ID: 27463363
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]